Schedule 13G ownership disclosure

Prelude Therapeutics, Inc.

Common Stock · CUSIP: 74065P101

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Deerfield Mgmt, L.P.

    Shares: 0.00 · Class: 0%

  • Deerfield Management Company, L.P.

    Shares: 0.00 · Class: 0%

  • Deerfield Partners, L.P.

    Shares: 0.00 · Class: 0%

  • James E. Flynn

    Shares: 0.00 · Class: 0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193805-25-000177
Form type
SCHEDULE 13G/A
Filer
Flynn James E
CIK
CIK 1352546
Filed
Feb 13, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub